Actinium Adds Industry Veteran to Lead Radiotherapy Partnerships and Licensing

Key Points

• Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026.
• He brings more than 20 years of oncology experience, including roles at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical.
• Maenpaa will lead partnering, licensing and strategic transactions across Actinium’s targeted radiotherapy pipeline.
• The appointment strengthens the company’s dealmaking team but does not include a new partnership or licensing agreement.

Actinium Pharmaceuticals (NYSE: ATNM) has hired Sean Maenpaa to lead its business development efforts as it seeks partnerships for its targeted radiotherapy programs.

His responsibilities include licensing Actinium’s assets to other companies, evaluating outside technologies and pursuing collaborations across its pipeline for blood cancers and solid tumors.

Experience Spans Drug Development, Commercialization and Isotope Supply

Maenpaa’s background covers several parts of the radiopharmaceutical business, including radioactive materials used in medicine, cancer treatments and diagnostic imaging agents.

At BWXT Medical, he oversaw business development and sales for more than $120 million in medical radioisotope supplies. At Telix Pharmaceuticals, he helped build its uro-oncology business and supported the growth of ILLUCCIX to $320 million in global sales.

At Clovis Oncology, he contributed to the sale of the FAP2286 radiotherapy program to Novartis. His earlier experience includes radiotherapy work at Bayer and blood-cancer strategy at Novartis and Celgene.

Actinium Wants to Turn Pipeline Expertise Into Partnerships

CEO Sandesh Seth said Maenpaa’s experience and industry relationships align with Actinium’s efforts to secure partnerships.

The company highlighted its expertise in Actinium-225, or Ac-225, and a targeted radiotherapy pipeline spanning blood cancers and solid tumors. Maenpaa will help identify opportunities to develop and commercialize those assets with partners.

Investor Takeaway

For ATNM investors, the hire adds relevant transaction and commercial experience to the leadership team. The next meaningful milestone will be whether that experience translates into signed agreements.

The announcement does not disclose a new deal, potential transaction value or an expected timeline for partnerships.